Literature DB >> 24188707

Prioritizing multipurpose prevention technology development and investments using a target product profile.

Joe Romano1, Judy Manning, Anke Hemmerling, Elizabeth McGrory, Bethany Young Holt.   

Abstract

Multipurpose prevention technologies (MPTs) represent a powerful opportunity to address the unmet sexual and reproductive health needs of women in at-risk populations around the world in an efficient and cost-effective manner. The development of MPT products for the combination prevention of pregnancy and sexually transmitted infections (including HIV) is a high-risk/high-gain, expensive process. The associated challenges are compounded by limitations in available resources for the development, evaluation, and delivery of such products. Consequently, an objective process for identifying MPT products with the highest public health impact potential is necessary to serve as the basis of coordinated investment of supporting agencies in the development of such products. Moreover, this process would serve as a framework for product development organizations, guiding their product development strategies. The Scientific Agenda Working Group of the Initiative for Multipurpose Prevention Technologies conducted an MPT pipeline evaluation exercise for the purpose of defining specific MPT product priorities, and to identify MPT technology gaps which need to be addressed in order to achieve development of optimal products. Through a formal and objective process, a set of MPT priority product recommendations emerged, along with several priority MPT gaps. Further, specific MPT development process priorities were identified. The detailed process and summary findings of this exercise are presented here. This article is based on a presentation at the "Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies," held in Arlington, Virginia on February 21-22, 2013. It forms part of a special supplement to Antiviral Research.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Contraception; HIV prevention; Multipurpose prevention technologies; STI prevention

Mesh:

Year:  2013        PMID: 24188707     DOI: 10.1016/j.antiviral.2013.09.016

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  11 in total

Review 1.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

2.  Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.

Authors:  K M Guthrie; L Rohan; R K Rosen; S E Vargas; J G Shaw; D Katz; E M Kojic; A S Ham; D Friend; K W Buckheit; R W Buckheit
Journal:  Pharm Dev Technol       Date:  2017-06-21       Impact factor: 3.133

3.  Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.

Authors:  Jenna S Hynes; Anandi N Sheth; Eva Lathrop; Jessica M Sales; Lisa B Haddad
Journal:  J Womens Health (Larchmt)       Date:  2019-01-04       Impact factor: 2.681

4.  Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.

Authors:  James M Smith; Priya Srinivasan; Ryan S Teller; Yungtai Lo; Chuong T Dinh; Patrick F Kiser; Betsy C Herold
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

5.  Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States.

Authors:  Jenna S Hynes; Jessica M Sales; Anandi N Sheth; Eva Lathrop; Lisa B Haddad
Journal:  Contraception       Date:  2017-10-18       Impact factor: 3.375

6.  Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.

Authors:  Ellen H Luecke; Helen Cheng; Kubashni Woeber; Teopista Nakyanzi; Imelda C Mudekunye-Mahaka; Ariane van der Straten
Journal:  J Int AIDS Soc       Date:  2016-05-30       Impact factor: 5.396

7.  Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.

Authors:  Alexandra M Minnis; Sarah T Roberts; Kawango Agot; Rachel Weinrib; Khatija Ahmed; Kgahlisho Manenzhe; Fredrick Owino; Ariane van der Straten
Journal:  AIDS Behav       Date:  2018-08

8.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

9.  Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women.

Authors:  Tania Crucitti; Liselotte Hardy; Janneke van de Wijgert; Stephen Agaba; Jozefien Buyze; Evelyne Kestelyn; Thérèse Delvaux; Lambert Mwambarangwe; Irith De Baetselier; Vicky Jespers
Journal:  PLoS One       Date:  2018-07-23       Impact factor: 3.240

10.  Bridging the gap: advancing multipurpose prevention technologies from the lab into the hands of women†.

Authors:  Bethany Young Holt; James Kiarie; Gregory S Kopf; Kavita Nanda; Anke Hemmerling; Sharon L Achilles
Journal:  Biol Reprod       Date:  2020-08-04       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.